A small-molecule HIF2α inhibitor PT2385, which was later improved to the second-generation inhibitor PT2977 (now known as ‘MK-6482’), has also been shown to block the transcription of HIF2α-responsive genes, including VEGFA, CCND1 and the glucose transporter–encoding gene SLC2A1, and both molecules demonstrated on-target antitumor activity in mouse xenograft models of renal cell cancer (20). Here, EPAS1 is linked to renal cell adenocarcinoma.